TW202142254A - 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 - Google Patents

用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 Download PDF

Info

Publication number
TW202142254A
TW202142254A TW110102010A TW110102010A TW202142254A TW 202142254 A TW202142254 A TW 202142254A TW 110102010 A TW110102010 A TW 110102010A TW 110102010 A TW110102010 A TW 110102010A TW 202142254 A TW202142254 A TW 202142254A
Authority
TW
Taiwan
Prior art keywords
mydgf
heart failure
fibrosis
hypertrophy
protein
Prior art date
Application number
TW110102010A
Other languages
English (en)
Chinese (zh)
Inventor
凱伊 沃勒特
克林格比爾 莫提摩 科爾夫
馬克 瑞波
Original Assignee
漢諾威醫學院
德商百靈佳殷格翰國際有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 漢諾威醫學院, 德商百靈佳殷格翰國際有限公司 filed Critical 漢諾威醫學院
Publication of TW202142254A publication Critical patent/TW202142254A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110102010A 2020-01-21 2021-01-19 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 TW202142254A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20153008 2020-01-21
EP20153008.6 2020-01-21

Publications (1)

Publication Number Publication Date
TW202142254A true TW202142254A (zh) 2021-11-16

Family

ID=69187588

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110102010A TW202142254A (zh) 2020-01-21 2021-01-19 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子

Country Status (12)

Country Link
US (1) US20230059560A1 (https=)
EP (1) EP4093750A1 (https=)
JP (1) JP7777532B2 (https=)
KR (1) KR20220131262A (https=)
CN (1) CN115698048A (https=)
AU (1) AU2021211874A1 (https=)
BR (1) BR112022014272A2 (https=)
CA (2) CA3164500A1 (https=)
MX (1) MX2022008727A (https=)
PH (1) PH12022551792A1 (https=)
TW (1) TW202142254A (https=)
WO (1) WO2021148411A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022066729A1 (en) * 2020-09-22 2022-03-31 Wisconsin Alumni Research Foundation Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor
US20250325704A1 (en) 2020-12-23 2025-10-23 Boehringer Ingelheim International Gmbh Viral capsid proteins with specificity to heart tissue cells
CN115820829B (zh) * 2022-03-22 2026-04-17 中国人民解放军军事科学院军事医学研究院 Mydgf在防治记忆损伤及其相关疾病中的应用
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
JP2025530232A (ja) 2022-09-08 2025-09-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心原性ショックの処置に用いる骨髄由来成長因子
EP4480490A1 (en) * 2023-06-23 2024-12-25 Medizinische Hochschule Hannover Brick1 for use in treating myocardial diseases
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202539726A (zh) 2023-12-06 2025-10-16 德商百靈佳殷格翰國際股份有限公司 包含骨髓衍生性生長因子之新穎調配物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
AU717542B2 (en) 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
JP2001506484A (ja) 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US20080004232A1 (en) 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP2130547A1 (en) 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
DK2945642T3 (da) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
JP7405772B2 (ja) * 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
WO2020176732A1 (en) * 2019-02-27 2020-09-03 Icahn School Of Medicine At Mount Sinai TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY

Also Published As

Publication number Publication date
PH12022551792A1 (en) 2023-09-18
EP4093750A1 (en) 2022-11-30
MX2022008727A (es) 2022-10-07
CA3164500A1 (en) 2021-07-29
AU2021211874A1 (en) 2022-08-25
WO2021148411A1 (en) 2021-07-29
JP7777532B2 (ja) 2025-11-28
KR20220131262A (ko) 2022-09-27
JP2023511358A (ja) 2023-03-17
CN115698048A (zh) 2023-02-03
US20230059560A1 (en) 2023-02-23
CA3223879A1 (en) 2021-07-29
BR112022014272A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
TW202142254A (zh) 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子
JP7305543B2 (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP4351896B2 (ja) ｐ３８／ＪＴＶ−１を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法
JP2025143268A (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP6401292B2 (ja) 抗ｎｍｅ抗体
JP6605467B2 (ja) Ｖｅｇｆ−ｃおよびｃｃｂｅ１の治療的使用
CN102112149A (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
CN113301914B (zh) 用于治疗和预防纤维化的组合物和方法
JP2009019032A (ja) 血管形成及び心臓血管新生の促進又は阻害
KR20150140686A (ko) 신증후군 및 관련 병태의 치료 방법
US11944671B2 (en) Hippo pathway deficiency reverses systolic heart failure post-infarction
TW201200151A (en) Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
CN116925205A (zh) 激活Hippo信号通路的多肽及其用途
EA053022B1 (ru) Фактор роста миелоидного происхождения для применения при лечении или профилактике фиброза, гипертрофии или сердечной недостаточности
Yang et al. Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation
HK40088501A (zh) 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子
HK40029335A (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
US20150190391A1 (en) Inhibitors of nkx2.5 for vascular remodelling